Approval · Notice of Compliance 36260 · 2025
MYFEMBREE: Notice of Compliance 36260
Issued October 28, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36260
- Date
- October 28, 2025
- Company
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Change in product ownership
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MYFEMBREE | 02541742 | Marketed |
Medicinal ingredients
- ESTRADIOL 1 MG per TAB
- NORETHINDRONE ACETATE 0.5 MG per TAB
- RELUGOLIX 40 MG per TAB